Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
74.04 (1y: +77%)
Market Cap 12.74 B P/E(ttm) 31.40
Enterprise Value 14.98 B P/B 2.71
LIFE- NAS (USA)
Life Technologies Corp
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$74.04
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 0.103
LIFE's Cash to Debt is ranked lower than
917430% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.36 vs. LIFE: 0.103 )
LIFE' s 10-Year Cash to Debt Range
Min: 0.09   Max: 148.86
Current: 0.1
0.09
148.86
Equity to Asset -0.159
LIFE's Equity to Asset is ranked lower than
1098900% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. LIFE: -0.159 )
LIFE' s 10-Year Equity to Asset Range
Min: -0.33   Max: 0.9
Current: -0.16
-0.33
0.9
Interest Coverage 5.5
LIFE's Interest Coverage is ranked lower than
1388888% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10000.00 vs. LIFE: 5.5 )
LIFE' s 10-Year Interest Coverage Range
Min: 2   Max: 29720
Current: 5.5
2
29720
F-Score: 6
Z-Score: 2.91
M-Score: -2.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 17.50
LIFE's Operating margin (%) is ranked higher than
71% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.50 vs. LIFE: 17.50 )
LIFE' s 10-Year Operating margin (%) Range
Min: -23.9   Max: 18.9
Current: 17.5
-23.9
18.9
Net-margin (%) 11.3
LIFE's Net-margin (%) is ranked lower than
1754384% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.60 vs. LIFE: 11.3 )
LIFE' s 10-Year Net-margin (%) Range
Min: -23.5   Max: 11.3
Current: 11.3
-23.5
11.3
ROE (%) 9.3
LIFE's ROE (%) is ranked lower than
1785713% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.30 vs. LIFE: 9.3 )
LIFE' s 10-Year ROE (%) Range
Min: -11.7   Max: 9.3
Current: 9.3
-11.7
9.3
ROA (%) 5
LIFE's ROA (%) is ranked lower than
1754384% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.40 vs. LIFE: 5 )
LIFE' s 10-Year ROA (%) Range
Min: -6   Max: 5
Current: 5
-6
5
ROC (Joel Greenblatt) (%) 48.60
LIFE's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.80 vs. LIFE: 48.60 )
LIFE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -65.8   Max: 63.7
Current: 48.6
-65.8
63.7
Revenue Growth (%) 4
LIFE's Revenue Growth (%) is ranked lower than
2173911% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.60 vs. LIFE: 4 )
LIFE' s 10-Year Revenue Growth (%) Range
Min: 4   Max: 34.9
Current: 4
4
34.9
EBITDA Growth (%) 5.2
LIFE's EBITDA Growth (%) is ranked lower than
3448272% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.80 vs. LIFE: 5.2 )
LIFE' s 10-Year EBITDA Growth (%) Range
Min: -73.8   Max: 372.4
Current: 5.2
-73.8
372.4
EPS Growth (%) 31.6
LIFE's EPS Growth (%) is ranked lower than
5882347% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.10 vs. LIFE: 31.6 )
LIFE' s 10-Year EPS Growth (%) Range
Min: -28.8   Max: 61.7
Current: 31.6
-28.8
61.7
» LIFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

LIFE Guru Trades in Q2 2012

Paul Tudor Jones 9,300 sh (New)
Zeke Ashton 55,000 sh (New)
Jeremy Grantham 6,400 sh (New)
Diamond Hill Capital 86,940 sh (+8.03%)
Robert Olstein 207,000 sh (+2.99%)
John Paulson 4,977,792 sh (unchged)
George Soros 51,831 sh (unchged)
PRIMECAP Management 14,869,870 sh (-0.03%)
Larry Robbins 11,705,472 sh (-0.43%)
Mario Gabelli 42,696 sh (-2.73%)
First Pacific Advisors 923,398 sh (-6.86%)
RS Investment Management 2,105,280 sh (-11.07%)
Murray Stahl 24,000 sh (-11.11%)
Joel Greenblatt 12,519 sh (-12.11%)
John Hussman 1,000,000 sh (-48.8%)
Ray Dalio 49,956 sh (-71.75%)
Steven Cohen 10,527 sh (-91.46%)
» More
Q3 2012

LIFE Guru Trades in Q3 2012

Ronald Muhlenkamp 218,140 sh (New)
John Rogers 1,488,160 sh (New)
John Paulson 13,513,800 sh (+171.48%)
Steven Cohen 23,228 sh (+120.65%)
Joel Greenblatt 26,136 sh (+108.77%)
Ray Dalio 67,312 sh (+34.74%)
Jeremy Grantham 6,600 sh (+3.13%)
Diamond Hill Capital 87,869 sh (+1.07%)
Murray Stahl 24,000 sh (unchged)
First Pacific Advisors 923,398 sh (unchged)
Paul Tudor Jones Sold Out
John Hussman Sold Out
Zeke Ashton Sold Out
George Soros Sold Out
PRIMECAP Management 14,829,254 sh (-0.27%)
Larry Robbins 11,444,515 sh (-2.23%)
Mario Gabelli 40,996 sh (-3.98%)
Robert Olstein 175,000 sh (-15.46%)
RS Investment Management 1,670,893 sh (-20.63%)
» More
Q4 2012

LIFE Guru Trades in Q4 2012

Paul Tudor Jones 6,800 sh (New)
Chuck Royce 33,000 sh (New)
Meridian Funds 380,400 sh (New)
Scott Black 8,275 sh (New)
Bruce Kovner 71,000 sh (New)
Ray Dalio 144,088 sh (+114.06%)
John Rogers 1,878,931 sh (+26.26%)
Diamond Hill Capital 93,314 sh (+6.2%)
John Paulson 14,000,000 sh (+3.6%)
Murray Stahl 24,000 sh (unchged)
Larry Robbins 350,000 sh (unchged)
PRIMECAP Management 14,793,545 sh (-0.24%)
Ronald Muhlenkamp 216,000 sh (-0.98%)
Larry Robbins 11,195,648 sh (-2.17%)
Mario Gabelli 39,896 sh (-2.68%)
First Pacific Advisors 876,398 sh (-5.09%)
Robert Olstein 161,000 sh (-8%)
Joel Greenblatt 21,461 sh (-17.89%)
RS Investment Management 1,185,197 sh (-29.07%)
Steven Cohen 8,632 sh (-62.84%)
» More
Q1 2013

LIFE Guru Trades in Q1 2013

Jeremy Grantham 18,500 sh (New)
Steven Cohen 25,000 sh (+189.62%)
Larry Robbins 14,539,992 sh (+29.87%)
Scott Black 8,885 sh (+7.37%)
John Paulson 14,773,700 sh (+5.53%)
Mario Gabelli 39,896 sh (unchged)
Bruce Kovner Sold Out
RS Investment Management Sold Out
Chuck Royce Sold Out
PRIMECAP Management 14,657,427 sh (-0.92%)
Murray Stahl 23,000 sh (-4.17%)
Meridian Funds 350,000 sh (-7.99%)
John Rogers 1,671,846 sh (-11.02%)
Diamond Hill Capital 73,906 sh (-20.8%)
Joel Greenblatt 16,192 sh (-24.55%)
First Pacific Advisors 585,598 sh (-33.18%)
Robert Olstein 99,000 sh (-38.51%)
Paul Tudor Jones 3,900 sh (-42.65%)
Ronald Muhlenkamp 50,000 sh (-76.85%)
Ray Dalio 24,408 sh (-83.06%)
» More
» Details

Insider Trades

Latest Guru Trades with LIFE

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2013-03-31 Reduce -76.85%1.77%$49.03 - $65.27 $ 74.0423%50000
John Paulson 2013-03-31 Add 5.53%0.28%$49.03 - $65.27 $ 74.0423%14773700
Ray Dalio 2013-03-31 Reduce -83.06%0.06%$49.03 - $65.27 $ 74.0423%24408
Joel Greenblatt 2013-03-31 Reduce -24.55%0.01%$49.03 - $65.27 $ 74.0423%16192
Meridian Funds 2012-12-31 New Buy0.73%$46.39 - $51.79 $ 74.0451%380400
John Paulson 2012-12-31 Add 3.6%0.15%$46.39 - $51.79 $ 74.0451%14000000
Scott Black 2012-12-31 New Buy0.06%$46.39 - $51.79 $ 74.0451%8275
Ray Dalio 2012-12-31 Add 114.06%0.04%$46.39 - $51.79 $ 74.0451%144088
John Paulson 2012-09-30 Add 171.48%3.41%$41.26 - $49.7 $ 74.0462%13513800
Ronald Muhlenkamp 2012-09-30 New Buy2.3%$41.26 - $49.7 $ 74.0462%218140
John Hussman 2012-09-30 Sold Out 0.85%$41.26 - $49.7 $ 74.0462%0
Joel Greenblatt 2012-09-30 Add 108.77%0.04%$41.26 - $49.7 $ 74.0462%26136
George Soros 2012-09-30 Sold Out 0.03%$41.26 - $49.7 $ 74.0462%0
Ray Dalio 2012-09-30 Add 34.74%0.01%$41.26 - $49.7 $ 74.0462%67312
John Hussman 2012-06-30 Reduce -48.8%0.88%$40.25 - $48.69 $ 74.0468%1000000
Ray Dalio 2012-06-30 Reduce -71.75%0.09%$40.25 - $48.69 $ 74.0468%49956
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Life Technologies Corp

Three Gurus Hold a Major Stake in LIFE
March 26, 2013
For the past few months, Life Technologies Corporation (LIFE), the global biotechnology company that makes DNA-sequencing equipment, laboratory instruments and lab testing products, is still in discussions with potential buyers. The company has over 50,0000 products and 5,000 patents used in cellular testing and research, forensics, food and water safety, animal health, clinical testing and numerous other applications in research science, applied science, and medical science. In its gene-sequencing sector, Life Technologies Corp. competes with Illumina Inc. (ILMN). Both California-based companies use technology that can “blueprint” a human being’s DNA for medical purposes in the emerging field of molecular diagnostics. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 31.40
LIFE's P/E(ttm) is ranked lower than
1612902% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.30 vs. LIFE: 31.40 )
LIFE' s 10-Year P/E(ttm) Range
Min: 12.15   Max: 2092.2
Current: 31.4
12.15
2092.2
P/B 2.71
LIFE's P/B is ranked lower than
1010100% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.64 vs. LIFE: 2.71 )
LIFE' s 10-Year P/B Range
Min: 0.78   Max: 14.84
Current: 2.71
0.78
14.84
P/S 3.43
LIFE's P/S is ranked lower than
917430% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.43 vs. LIFE: 3.43 )
LIFE' s 10-Year P/S Range
Min: 1.4   Max: 27.27
Current: 3.43
1.4
27.27
PFCF 19.64
LIFE's PFCF is ranked lower than
1724136% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.60 vs. LIFE: 19.64 )
LIFE' s 10-Year PFCF Range
Min: 8.06   Max: 269.62
Current: 19.64
8.06
269.62
EV-to-EBIT 23.01
LIFE's EV-to-EBIT is ranked lower than
1219511% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.90 vs. LIFE: 23.01 )
LIFE' s 10-Year EV-to-EBIT Range
Min: 11   Max: 182.6
Current: 23.01
11
182.6
PEG 1.74
LIFE's PEG is ranked lower than
4999995% of the 20 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. LIFE: 1.74 )
LIFE' s 10-Year PEG Range
Min: 0.35   Max: 2.14
Current: 1.74
0.35
2.14
Shiller P/E 45.45
LIFE's Shiller P/E is ranked lower than
100% of the Companies
in the Global Diagnostics & Research industry.

( Industry Median: vs. LIFE: 45.45 )
LIFE' s 10-Year Shiller P/E Range
Min: 31.44   Max: 1045.25
Current: 45.45
31.44
1045.25

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 17.9
LIFE's Price/Net Current Asset Value is ranked lower than
1149424% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.80 vs. LIFE: 17.9 )
LIFE' s 10-Year Price/Net Current Asset Value Range
Min: 4.1   Max: 31
Current: 17.9
4.1
31
Price/DCF (Projected) 1.1
LIFE's Price/DCF (Projected) is ranked lower than
2702700% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. LIFE: 1.1 )
LIFE' s 10-Year Price/DCF (Projected) Range
Min: 0.7   Max: 2.5
Current: 1.1
0.7
2.5
Price/Median PS Value 1.1
LIFE's Price/Median PS Value is ranked lower than
1041666% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. LIFE: 1.1 )
LIFE' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 4.1
Current: 1.1
0.5
4.1
Price/Peter Lynch Fair Value 2
LIFE's Price/Peter Lynch Fair Value is ranked lower than
7142850% of the 14 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. LIFE: 2 )
LIFE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.8   Max: 5.5
Current: 2
0.8
5.5
Earnings Yield (Greenblatt) 4.30
LIFE's Earnings Yield (Greenblatt) is ranked lower than
63% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. LIFE: 4.30 )
LIFE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 9.1
Current: 4.3
0.5
9.1
Forward Rate of Return (Yacktman) 18.23
LIFE's Forward Rate of Return (Yacktman) is ranked lower than
3030300% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.26 vs. LIFE: 18.23 )
LIFE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.4   Max: 61.9
Current: 18.23
0.4
61.9

Business Description

Life Technologies Corp began operations as a California partnership in 1987 and incorporated in California in 1989. In 1997, the Company reincorporated as a Delaware corporation. On November 21, 2008, Invitrogen Corporation, a predecessor company to Life Technologies, completed the acquisition of Applied Biosystems, Inc. to form a new company called Life Technologies Corporation. Life Technologies Corporation is a global biotechnology tools company dedicated to improving the human condition. The Company's systems, consumables and services enable researchers and commercial markets to accelerate scientific exploration, to discoveries and developments that better the quality of life. The Company's products are also used in forensics, food and water testing and other industrial applications. The Company delivers a range of products and services, including systems, instruments, reagents, software, and custom services. Its growing portfolio of products includes innovative technologies for capillary electrophoresis-based sequencing, next generation sequencing, PCR, sample preparation, cell culture, RNA interference analysis, functional genomics research, proteomics and cell biology applications, as well as clinical diagnostic applications, forensics and animal, food, pharmaceutical and water testing analysis. The Company also provides its customers convenient and value-added purchasing options through thousands of sales and service professionals, e-commerce capabilities and onsite supply center solutions. The Company operates is business under three divisions: Molecular Biology Systems ('MBS'), Cell Systems ('CS'), and Genetic Systems ('GS'). The MBS division includes the molecular biology-based technologies, including basic and real-time PCR, RNAi, DNA synthesis, sample prep, transfection, cloning and protein expression profiling, protein analysis and thermo-cycler instrumentation. The CS division includes all product lines used in the study of cell function, including cell culture media and sera, stem cells and related tools, cellular imaging products, antibodies, drug discovery services and cell therapy related products. The GS division includes capillary electrophoresis systems and reagents and next generation sequencing systems and reagents, including the SOLiDTM and Ion TorrentTM systems, as well as reagent kits developed specifically for applied markets, such as forensics and food safety, animal health and pharmaceutical quality monitoring. The Company offers many different products and services and is continually developing and/or acquiring others. Some of its specific product categories include the following: 'High-throughput' gene cloning and expression technology; Pre-cast electrophoresis products; Antibodies; Magnetic beads; Molecular Probes fluorescence-based technologies; Transfection reagents; PCR and Real Time PCR systems and reagents; and RNA Interference reagents. The Company's manufacturing operations require a variet
Company Website
SEC Reports
Industry: Diagnostics & Research
Compare:LH, ALR, DGX, ENZ, IDXX
Traded in other countries:IVN.Germany
» More Articles for LIFE

Headlines

Articles On GuruFocus.com
Three Gurus Hold a Major Stake in LIFE Mar 26 2013 
Why Is Life (LIFE) Cheap? Mar 18 2013 
Quick Rise, Sharp Pullback- That’s LIFE Feb 24 2013 
Delphi Management's Scott Black Releases Fourth Quarter New Stocks Jan 31 2013 
My Best Healthcare Stock Picks For 2013 | Last Year’s Picks Gained 31.55% Dec 04 2012 
John Rogers' Ariel Fund Q3 Commentary Oct 25 2012 
Larry Robbins' Top Conviction Picks - 'In Glenview, we like health care and industrial solid compani Jan 31 2012 
Hedge Fund Glenview Capital Larry Robbins Buys BMC Software, HCA Holdings, Sealed Air, Sells Aetna I Nov 16 2011 
John Hussman and Hussman Econometric Advisors Top Stocks : HUM, AZN, PNRA, ARO, LIFE May 16 2011 
Right with Stock Picking, Wrong on Macro Trends; John Hussman’s Top Holdings Feb 22 2011 

More From Our Partners
MedTech Industry Stock Update - May 2013 - Zacks Analyst Interviews May 15 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial